Retatrutide 12 mg linked to 18.8% weight loss in adults with obesity and type 2 diabetes
Primary endpointPercentage change from baseline to week 80 in bodyweight for the retatrutide 9 mg and 12 mg doses versus placebo
Where these numbers come from
“For the treatment regimen estimand, the mean percentage change from baseline in bodyweight at week 80 was -11.9% (SE 0.6) with retatrutide 4 mg, -16.8% (0.7) with retatrutide 9 mg, -18.8% (0.7) with retatrutide 12 mg, and -5.1% (0.7) with placebo.”
The publication
In a phase 3 trial, adults with obesity and type 2 diabetes who received retatrutide 12 mg once weekly had a mean bodyweight change of -18.8% at week 80, compared with -5.1% for placebo. The authors concluded that retatrutide might be effective for treating obesity in this population.
Who the findings apply to
The trial enrolled adults aged 18 years or older with a BMI of 27 kg/m2 or higher and type 2 diabetes, defined as a glycated haemoglobin (HbA1c) of 6.5% to 10.5%.
Participants were required to be on stable treatment for type 2 diabetes for at least 90 days before screening, which could include diet or exercise alone, or up to three oral glucose-lowering medications.
Eligible participants also needed a history of at least one self-reported unsuccessful dietary effort to reduce bodyweight.
Why this matters
The trial addresses the need for effective weight management in patients with both obesity and type 2 diabetes. The authors state that treatment resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism.
What the study found
At week 80, the mean percentage change from baseline in bodyweight was -11.9% (SE 0.6) with retatrutide 4 mg, -16.8% (0.7) with retatrutide 9 mg, -18.8% (0.7) with retatrutide 12 mg, and -5.1% (0.7) with placebo.
Estimated treatment differences compared with placebo for percentage change in bodyweight were -6.9% (95% CI -8.7 to -5.1) with retatrutide 4 mg, -11.8% (-13.7 to -9.8) with retatrutide 9 mg, and -13.8% (-15.8 to -11.8) with retatrutide 12 mg (p<0.0001 for all).
The authors reported that treatment with retatrutide was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes.
What the result does not establish
Gastrointestinal adverse events were more common in the retatrutide groups than in the placebo group, with diarrhoea occurring in 80 [27%] of 292 participants in the 4 mg group, 95 [34%] of 284 in the 9 mg group, and 96 [34%] of 286 in the 12 mg group vs 38 [13%] of 287 in the placebo group.
Nausea occurred in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%] in the placebo group.
Permanent treatment discontinuation due to adverse events or death was more frequent in participants treated with retatrutide 9 mg (33 [12%]) and 12 mg (22 [8%]) compared with retatrutide 4 mg (11 [4%]) and placebo (14 [5%]).
The study was funded by Eli Lilly and Company, and the authors note that the results show retatrutide might be effective, rather than definitively proving efficacy.
Authors’ conclusion
“Treatment with retatrutide resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism. These results show that retatrutide might be effective for the treatment of obesity in people with type 2 diabetes.”
Trial registration
| Registered title | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) |
|---|---|
| Registry status | Phase 3, interventional, active not recruiting |
| Lead sponsor | Eli Lilly and Company |
| Registered size | 1,000 participants — planned enrolment (estimate) |
| Where | 98 sites in 8 countries (Argentina, Australia, Brazil, India, Mexico, Romania and 2 more) |
| Registered primary outcomes |
Primary endpoint named in the abstract: the percentage change from baseline to week 80 in bodyweight for the retatrutide 9 mg and 12 mg doses versus…. Compare the two: a change of primary endpoint after registration matters. |
- Start: Jul 2023
- Completion: May 2026 (estimated; this date has passed — check the registry)
- Primary completion: May 2026 (estimated; this date has passed — check the registry)
- Paper published: Sep 2026
ClinicalTrials.gov record as held by ENCLAI, last updated Apr 2025. The registry status may have changed since; the link shows the current record.
Study and sources
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Randomised trial · Phase 3 · Lancet · 2026-09-29
Sources and limitations
- PubMed record PMID 42810372 (PubMed / NLM · 2026-09-30)
- Trial registry NCT05929079 (ClinicalTrials.gov · 2026-09-30)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


